All lobbying filings

ADVANCED POLICY CONSULTING, LLC

ADVANCED POLICY CONSULTING, LLC filed a Q4 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) on January 17, 2026, reporting $40,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Trade association for the Pharmaceutical Research and Manufacturer's of America

All filings by ADVANCED POLICY CONSULTING, LLC · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Monitoring healthcare legislation. Education regarding market based solutions to bring down the cost of drug prices. Education regarding the dangers of global counterfeit medications. Education regard the International Pricing Index (IPI) Model, which would import single-payer government run price controls that limit innovation and patient access to life saving therapies. Support for PBM reform. HR 2214 -- "DRUG Act" HR 1492 -- "To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program." S.832 - "EPIC Act of 2025." Education regarding the Most Favored Nation Executive Order.

Bills named in this filing 3

H.R. 2214
DRUG Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.